Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HLB Panagene CoXKRX:046210 -0.37%50 EBITDA Margin % is 8.43% as of Mar. 2026, which is 77% above its 10-year median of 4.76. GuruFocus rates XKRX:046210 with a GF Score™ of 50/100 and a GF Value™ of ₩3,114.45 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 940 Biotechnology companies, HLB Panagene Co ranks better than 66.91% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. HLB Panagene Co's EBITDA for the
three
months ended in Mar. 2026 was ₩264 Mil. HLB Panagene Co's Revenue for the
three
months ended in Mar. 2026 was ₩3,130 Mil. Therefore, HLB Panagene Co's EBITDA margin for the quarter that ended in Mar. 2026 was 8.43%.
HLB Panagene Co (XKRX:046210) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HLB Panagene Co EBITDA Margin % Related Terms
HLB Panagene Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for HLB Panagene Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:046210 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, HLB Panagene Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLB Panagene Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HLB Panagene Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HLB Panagene Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLB Panagene Co (XKRX:046210) has a EBITDA Margin % of 8.43% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HLB Panagene Co and its competitors. This is 77% above median its historical median of 4.76. According to the industry distribution chart, HLB Panagene Co ranks #311 out of 940 companies in the Biotechnology industry, placing it in the top 33.1%.
Is HLB Panagene Co's EBITDA Margin % too high?
HLB Panagene Co's current EBITDA Margin % of 8.43% is 77% above median its 10-year median of 4.76. Based on the distribution chart, HLB Panagene Co ranks #311 out of 940 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HLB Panagene Co has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HLB Panagene Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HLB Panagene Co ranks #311 out of 940 companies for EBITDA Margin %. This puts HLB Panagene Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HLB Panagene Co and its competitors. HLB Panagene Co's current EBITDA Margin % is 8.43%, which is 77% above median its own 10-year median of 4.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLB Panagene Co stock overvalued right now?
Based on GuruFocus' analysis, HLB Panagene Co (XKRX:046210) is currently considered Possible Value Trap. The stock's GF Value™ is ₩3,114.45, compared to a current price of ₩1,064.00 — trading 65.8% below its estimated fair value. The current EBITDA Margin % is 8.43%, which is 77% above median its 10-year median of 4.76. HLB Panagene Co's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HLB Panagene Co (XKRX:046210), the current EBITDA Margin % is 8.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLB Panagene Co (XKRX:046210) Overvalued in 2026?
Based on GuruFocus' analysis, HLB Panagene Co stock appears to be undervalued.
The current stock price of ₩1,064.00 is trading 65.8% below its estimated GF Value™ of ₩3,114.45.
GuruFocus considers HLB Panagene Co to be Possible Value Trap.
Key valuation signals for XKRX:046210:
EBITDA Margin %: 8.43% (77% above median its 10-year median of 4.76)
GF Value™: ₩3,114.45 vs. price of ₩1,064.00 (65.8% below fair value)
No single metric tells the full story. See the XKRX:046210 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLB Panagene Co Ltd is a South Korea-based company that operates as a specialized bio venture company. The group is developing various technologies and products utilizing PNA (Peptide Nucleic Acid), an artificial gene.
50GF Score
Get the complete analysis for XKRX:046210
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:046210 has been successfully added to your 
